publication . Preprint . 2010

Does Prescription Drug Adherence Reduce Hospitalizations and Costs?

William Encinosa; Didem Bernard; Avi Dor;
Open Access
  • Published: 01 Jan 2010
Abstract
We estimate the impact of diabetic drug adherence on hospitalizations, ER visits, and hospital costs, using insurance claims from MarketScan® employer data. However, it is often difficult to measure the impact of drug adherence on hospitalizations since both adherence and hospitalizations may be correlated with unobservable patient severity. We control for such unobservables using propensity score methods and instrumental variables for adherence such as drug coinsurance levels and direct-to- consumer-advertising. We find a significant bias due to unobservable severity in that patients with more severe health are more apt to comply with medications. Thus, the rel...
Subjects
free text keywords: jel:H51, jel:I11
19 references, page 1 of 2

Baum, C., Shaffer, M. and Stillman, S. (2003), “Instrumental Variables and GMM: Estimation and Testing.” The Stata Journal, Vol. 3 No. 1, pp. 1-31.

Becker, S. and Ichino, A. (2002), “Estimation of Average Treatment Effects Based on Propensity Scores.” The Stata Journal, Vol. 2 No. 4, pp. 358-377.

Bradford, D. et al. (2006), “Effects of Direct-to-Consumer Advertising of Hydroxymethylglutaryl Coenzyme A Reductiase Inhibitors on Attainment of LDL-C Goals”, Clinical Therapeutics, Vol. 23 No. 12, pp. 2105-18.

Dezii, C.M. (2000), “Medication Noncompliance: What is the Problem?”, Managed Care, Vol. 9 No. 9, pp. 7-12.

Dor, A. (2004), “Optimal Price Rules, Administered Prices and Suboptimal Prevention: Evidence from a Medicare Program”, Journal of Regulatory Economics, Vol. 25 No. 1, pp. 81-104.

Dor, A. and Encinosa, W. (2004), “Does Cost-Sharing Affect Compliance? The Case of Prescription Drugs”, National Bureau of Economic Research Working Paper 10738, September, 2004. NBER: Cambridge, MA.

Dor, A. and Encinosa, W. (2010), “How Does Cost-Sharing Affect Drug Purchases? Insurance Regimes in the Private Market for Prescription Drugs. Journal of Economics and Management Strategy, 19:3 forthcoming. [OpenAIRE]

Fendrick, A.M., Smith, D.G., Chernew, M.E., et al. (2001), “A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost”, American Journal of Managed Care, Vol. 7 No. 9, pp. 861-867.

Frank, R.G. and Newhouse, J.P. (2008), “Should Drug Prices Be Negotiated Under Part D of Medicare? And If So, How?”, Health Affairs, Vol. 27 No. 1, pp. 33-42.

Fuhrmans, V. (2004), “A Radical Prescription”, Wall Street Journal, May, 10, 2004. pp.

R3-R4.

Garber, Alan M. and McClellan, Mark B. (2007), “Satisfaction Guaranteed---“Payment by Results” for Biologic Agents”, New England Journal of Medicine, Vol. 357 No. 16, pp. 1575-1577.

Gaynor, Martin, Li, Jian and Vogt, William B. (2007), “Substitution, Spending Offsets, and Prescription Drug benefit Design”, Forum for Health Economics and Policy, Vol. 10 No. 2, pp. 1-31.

Gibson TB, Ozminkowski RJ, and Goetzel RZ. (2005), “The effects of prescription drug cost sharing: a review of the evidence”, American Journal of Managed Care, Vol. 11 No. 11, pp. 730-740.

Goldman, Dana P., Joyce, Geoffrey F. and Zheng, Yuhui (2007), “Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health”, Journal of the American Medical Association, Vol. 298 No. 1, pp. 61-69, E1- E18.

19 references, page 1 of 2
Any information missing or wrong?Report an Issue